GLP-1 drugs like semaglutide, the active ingredient in Novo Nordisk’s Ozempic and Wegovy, were originally intended to treat diabetes — and didn’t become blockbuster prescriptions until doctors realized that they were also potent weight loss aids that seem to re-wire patients’ relationship to food and satiety.

Since then, it’s slowly been emerging that they have another surprising effect: many users report less of a desire to throw back as many drinks as they did before starting the injections. Indeed, several small studies have found promising evidence that the drugs indeed curb cravings for alcohol, cigarettes, and even opioids, meaning they also hold promise to treat a range of addiction disorders.

Exactly why remains hazy, though. It’s generally established that GLP-1s target the brai

See Full Page